Lv5
980 积分 2023-07-11 加入
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
1天前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1天前
已完结
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
1天前
已完结
Cancer burden and control in China: landscape, trends and challenges
1天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
10天前
已完结
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
1个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
1个月前
已完结
The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis
1个月前
已完结
皖公网安备34019202002308
